Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...

A team of researchers at the Broad Institute, led by gene-editing pioneer David Liu, has developed a new genome-editing strategy that could potentially lead to a one-time treatment for multiple ...

A new genome editing tool—minimal versatile genetic perturbation technology (mvGPT)—can achieve simultaneous and orthogonal gene editing and gene regulation in human cells. The coming together of ...

Like base editing, prime editing offers a safer way to genome editing by relying on a nickase enzyme that “nicks” one DNA strand at a time, rather than cutting both simultaneously. Then, with the ...

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented ...

The CRISPR gene editing system holds tremendous promise. It has already revolutionized biomedical research by making gene editing a straightforward process. It involves using a guide RNA molecule that ...

Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with poor ...

For several years, a rivalry has been brewing between two high-profile gene-editing companies. On one hand is Prime Medicine, built on prime editing, a technology out of David’s Liu lab at the Broad ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...